Full text
Earnings transcript
Read the complete earnings call transcript.
QTRX
Quanterix Corporation
$3.16
0.07
(2.26%)
| Exchange: | NASDAQ |
| Market Cap: | 148.845M |
| Shares Outstanding: | 16.207M |
Delayed data
About The Company
| Sector: | Healthcare | |||||
| Industry: | Medical – Devices | |||||
| CEO: | Everett V. Cunningham | |||||
| Full Time Employees: | 471 | |||||
| Address: |
| |||||
| Website: | https://www.quanterix.com |
Quanterix Corporation, based in Billerica, Massachusetts, is a life sciences enterprise dedicated to pioneering and commercializing advanced digital immunoassay platforms. These sophisticated systems are designed to enhance precision health in both scientific research and diagnostic applications, reaching markets across North America, Europe, the Middle East, Africa, and the Asia Pacific regions. The company’s core offerings include several innovative instruments: The HD-X instrument, which provides highly sensitive and automated multiplex protein detection. The SR-X instrument, enabling researchers to leverage Simoa detection technology for diverse uses, such as the direct detection of nucleic acids. The SP-X instrument, which utilizes Simoa planar array technology for conducting multiplex chemiluminescent immunoassays. Alongside these platforms, Quanterix also supplies crucial consumables, including assay kits and reagents. In addition to its product line, the company delivers various contract research services, encompassing sample analysis, the development of custom “homebrew” assays, and other specialized research and development projects. Quanterix’s operational focus spans critical health areas like neurology, oncology, cardiology, infectious diseases, and inflammation. Its clientele within the life science research sector primarily consists of laboratories affiliated with academic and governmental research institutions, as well as pharmaceutical, biotechnology, and contract research organizations. Sales are managed through a multifaceted approach, combining a direct sales force, dedicated support organizations, and a network of distributors or sales agents. The company was initially incorporated in 2007 as Digital Genomics, Inc., before rebranding to Quanterix Corporation in August of the same year.
Click to read more…
Revenue Segmentation
EPS
Historical EPS and analyst estimates in one chart. Log in for the full interactive view and links to detailed estimates.
Earnings Call
AI summary
Key takeaways
Short, structured highlights from the call so you can focus on what matters.
Log in to continue
Log in to read the full transcript and AI-generated earnings summaries.
Login — it's freeIncome Statement
| Year | 2023 | 2024 | 2025 |
|---|---|---|---|
| Revenue | 121,139 | 135,436 | 138,654 |
| Gross Profit | 72,995 | 81,119 | 64,716 |
| EBITDA | -36,373 | -44,260 | -90,890 |
| Operating Income | -45,991 | -52,616 | -109,815 |
| Net Income | -28,354 | -38,531 | -107,150 |
(* All numbers are in thousands)
Balance Sheet
| Year | 2023 | 2024 | 2025 |
|---|---|---|---|
| Total Assets | 425,011 | 406,533 | 418,766 |
| Total Liabilities | 78,084 | 76,495 | 123,036 |
| Total Stockholders Equity | 346,927 | 330,038 | 295,730 |
| Total Debt | 41,464 | 37,371 | 37,239 |
| Cash and Cash Equivalents | 174,422 | 56,709 | 29,839 |
(* All numbers are in thousands)
Cash Flow Statement
| Year | 2023 | 2024 | 2025 |
|---|---|---|---|
| Operating Cash Flow | -18,902 | -35,164 | -77,236 |
| Capital Expenditure | -3,788 | -3,368 | -2,612 |
| Free Cash Flow | -22,690 | -38,532 | -79,848 |
| Net Income | -32,334 | -38,531 | -107,150 |
| Net Change in Cash | -164,311 | -117,707 | -26,139 |
(* All numbers are in thousands)
Analyst Estimates
| Fiscal Year | 2030 | Full Access | Full Access | Full Access | Full Access |
|---|---|---|---|---|---|
| Estimated Revenue (Low) | 266,482.659 | Full Access | Full Access | Full Access | Full Access |
| Estimated Revenue (High) | 270,083.902 | Full Access | Full Access | Full Access | Full Access |
| Estimated Revenue (Avg) | 268,399.999 | Full Access | Full Access | Full Access | Full Access |
| Estimated Ebitda (Low) | -129,263.670 | Full Access | Full Access | Full Access | Full Access |
| Estimated Ebitda (High) | -127,540.095 | Full Access | Full Access | Full Access | Full Access |
| Estimated Ebitda (Avg) | -128,457.745 | Full Access | Full Access | Full Access | Full Access |
| Estimated Net Income (Low) | -52,014.038 | Full Access | Full Access | Full Access | Full Access |
| Estimated Net Income (High) | -51,113.928 | Full Access | Full Access | Full Access | Full Access |
| Estimated Net Income (Avg) | -51,593.191 | Full Access | Full Access | Full Access | Full Access |
| Estimated SGA Expense (Low) | 226,569.618 | Full Access | Full Access | Full Access | Full Access |
| Estimated SGA Expense (High) | 229,631.477 | Full Access | Full Access | Full Access | Full Access |
| Estimated SGA Expense (Avg) | 228,199.785 | Full Access | Full Access | Full Access | Full Access |
| Estimated EPS (Avg) | -1.210 | Full Access | Full Access | Full Access | Full Access |
| Estimated EPS (High) | -1.200 | Full Access | Full Access | Full Access | Full Access |
| Estimated EPS (Low) | -1.220 | Full Access | Full Access | Full Access | Full Access |
| Number of Analysts (Estimated Revenue) | 1 | Full Access | Full Access | Full Access | Full Access |
| Number of Analysts (Estimated EPS) | 1 | Full Access | Full Access | Full Access | Full Access |
Log in to continue
Log in and subscribe to Full Access to see up to 5 years of analyst estimates.
Login — it's free(* All numbers are in thousands)
Current Key Metrics
Log in to continue
Log in to see all key valuation metrics and ratios for this symbol.
Login — it's freeForward P/E Ratios
Log in to continue
Log in with Full Access for forward P/E high/low estimates and the full multi-year table.
Login — it's freeSWOT Analysis
Strengths (preview)
- Consistent Revenue Growth: Quanterix has reported its seventh consecutive quarter of double-digit revenue growth in Q4 2024, as highlighted in the earnings call transcript. This performance indicates strong market demand for its products and operational effectiveness, positioning the company favorably within the biotechnology sector.
- Innovation-Driven Product Portfolio: The earnings call emphasized a focus on product innovation, with new offerings contributing to revenue streams. This aligns with industry trends favoring cutting-edge solutions in diagnostics and life sciences, enhancing QTRX’s competitive edge.
- Solid Financial Position: Based on balance sheet data, QTRX maintains a healthy level of cash and cash equivalents relative to total liabilities, providing financial flexibility for R&D and strategic initiatives. This stability supports sustained growth compared to industry peers.
Log in with Full Access for Weaknesses, Opportunities, Threats, and the complete SWOT.
At what price to buy it? -
Intrinsic Value Calculator
This is an automatic estimate. The most reliable way to know fair value for your own assumptions is to run the calculator below.
[intrinsic_calculator]
Common questions about QTRX valuation
Is Quanterix Corporation (QTRX) overvalued or undervalued right now?
MARKETSnap estimates intrinsic value for Quanterix Corporation (QTRX) using its proprietary valuation methodology, which incorporates discounted cash flow (DCF) analysis together with long-term earnings and fundamentals assumptions. By comparing intrinsic value to the current market price, long-term investors can see whether the stock screens as potentially overvalued, fairly valued, or undervalued today.
Is QTRX a buy, hold, or sell for long-term investors?
MARKETSnap does not give one-word “buy” or “sell” calls. Instead, it shows whether QTRX trades at a premium or discount to its estimated intrinsic value, how sensitive that value is to growth and margin assumptions, and how the stock fits into a diversified, long-term portfolio so investors can make their own buy, hold, or sell decision.
What is QTRX’s P/E ratio?
You can see QTRX’s trailing P/E (TTM) and forward P/E estimates in the Current Key Metrics and Forward P/E Ratios sections above. The P/E ratio compares the current share price to earnings per share and helps investors gauge valuation relative to earnings.
How is intrinsic value calculated for QTRX?
MARKETSnap uses its own valuation framework—not a generic spreadsheet DCF alone. Future cash flows and earnings are projected, discounted, and combined with MARKETSnap’s methodology so intrinsic value reflects fundamentals and long-term assumptions. You can run your own inputs and see the result using the Intrinsic Value Calculator above.
Is QTRX a good long-term investment?
Whether QTRX fits a long-term portfolio depends on your assumptions about growth, margins, and risk. MARKETSnap provides the metrics, intrinsic value calculator, and SWOT context so you can form your own view rather than rely on a single buy/sell rating.
QTRX
1-day price chart preview. Log in for 1W through 5Y ranges and period tabs.
Daily snapshot
2.26
Trading Metrics:
| Open: | 3.1 | Previous Close: | 3.09 | |
| Day Low: | 3.06 | Day High: | 3.21 | |
| Year Low: | 2.4 | Year High: | 8.77 | |
| Price Avg 50: | 3.19 | Price Avg 200: | 5.2 | |
| Volume: | 57168 | Average Volume: | 1.121M |
Log in to continue
Log in for multi-period charts (1W–5Y), period tabs, and the same layout as members.
Login — it's freeQTRX full analysis
Welcome to MARKETSNAP’s SWOT analysis for Quanterix Corporation, also known by its ticker QTRX. If you’re a long-term investor looking to dig into a unique player in the biotech space, you’ve come to the right place. Today, we’re breaking down what makes Quanterix tick, from its financials to its market position, and giving you a full picture through a detailed SWOT analysis. So, grab a coffee, let’s dive in, and figure out if this stock deserves a spot in your…
